Gene therapy for ovarian cancer: Development of novel treatment strategies

International Journal of Gynecological Cancer

Volumn 7, Issue 1, 1997, Pages 1-13

  Dorigo, O ^a   Berek, J S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

gene therapy; neoplasm; ovarian cancer; review

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PLASMID DNA; RECOMBINANT DNA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; DNA DETERMINATION; DNA RECOMBINATION; FEMALE; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0031022738     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00411.x     Document Type: Review

References (100)

1. Sobol RE, Shawler DL, Dorigo O, Gold D, Royston I, Fakhrai H. Immunogene therapy of cancer. In: Sobol RE, Scanlon KJ, eds. The Internet Book of Gene Therapy. Norwalk: Appleton and Lange, 1995: 171-80.
2. Vile R, Russell SJ. Gene transfer technologies for the gene therapy of cancer. Gene Therapy 1995; 1: 88-9.
3. Kriegler M. Gene Transfer and Expression. A Laboratory Manual. New York: Stockton Press, 1990.
4. Madaio MP, Hodder S, Schwartz B, Stollar BD. Responsiveness of autoimmune and normal mice to nucleic acid antigens. J Immunol 1984; 132: 872-6.
5. Chonn A, Cullis PR. Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 1995; 6: 698-708.
6. Hofland H, Huang L. Inhibition of human ovarian carcinoma cell proliferation by liposome-plasmid DNA complex. Biochem Biophys Res Commun 1995; 207: 492-6.
7. Son K, Huang L. Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer. Proc Natl Acad Sci USA 1994; 91: 12669-72.
8. Miller AD. Retroviral vectors. Curr Top Microbiol Immunol 1993; 3: 102-9.
9. Kremer EJ, Perricaudet M. Adenovirus and adeno-associated virus mediated gene transfer. Br Med Bull 1995; 51; 31-44.
10. Anderson JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus simplex vectors: Extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Hum Gene Ther 1992; 3: 487-99.
11. Curiel DT. High-efficiency gene transfer mediated by adenovirus-polylysine-DNA complexes. Ann N Y Acad Sci 1994; 716: 36-56; discussion 56-8.
12. Jolly D. Viral vectors systems for gene therapy. Cancer Gene Ther 1994; 1(Suppl. 1): 51-64.
13. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs in cells that are activly replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-42.
14. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host range. Proc Natl Acad Sci USA 1988; 85: 6460-4.
15. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167: 400-6.
16. Welsh RM, Cooper NR, Jensen FC, Oldstone MBA. Human serum lyses RNA tumour viruses. Nature 1975; 256: 612-14.
17. Federico M, Nappi F, Ferrari G, et al. A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus. J Virol 1995; 69: 6618-26.
18. Gregory S, Collman R, James W, et al. HIV-1 pseudotype virus containing a local virus genome and an HIV envelope: construction, assay and use. J Virol Methods 1993; 44: 287-304.
19. Payne LN, Howes K, Gillespie AM, Smith LM. Host range of Rous sarcoma virus pseudotype RSV (HPRS-103) in 12 avian species: support for a new avian retrovirus envelope subgroup, designated J. J Gen Virol 1992; 73: 2995-7.
20. McGuigan LC, Stallard V, Roos JM, Payne LG. Recombinant-expressed virus-like particle pseudotypes as an approach to vaccine development. Vaccine 1993; 11: 675-8.
21. Berns KI, Giraud C. Adenovirus and adeno-associated virus as vectors for gene therapy. Ann N Y Acad Sci 1995; 772: 95-104.
22. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207-20.
23. Bass C, Cabrera G, Elgavish A, et al. Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo. Cancer Gene Ther 1995; 2: 97-104.
24. Addison CL, Braciak T, Ralston R, et al. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA 1995; 92: 8522-6.
25. Michael SI, Hong JS, Curiel DT, Engler JA. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 1995; 2: 660-8.
26. Michael SI, Curiel DT. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther 1994; 1: 223-32.
27. Forni G, Giovarelli M, Santoni A. Lymphokine-activated tumor inhibition in vivo. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol 1985, 135: 1305-11.
28. Garver RI, Goldsmith KT, Roud B, et al. Strategy for achieving selective killing of carcinomas. Gene Ther 1994; 1: 46-50.
29. Ley V, Langlade-Demoyen P, Kourilsky P, Larsson-Sciard EL. Interleukin 2 dependent activation of tumor- specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991; 21: 851-4.
30. Erard F, Corthesy P, Nabholz M, et al. Interleukin 2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocytes precursors. J Immunol 1985; 134: 1644-52.
31. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-41.
32. Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1994; 1: 436-50.
33. Howard B, Burrascano M, McCallister T, et al. Retrovirus-mediated gene transfer of the human γ-IFN gene: a therapy for cancer. Ann NY Acad Sci 1994; 716: 167-87.
34. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs. Blood 1994; 83: 1289-98.
35. McBride WH, Dougherty GD, Wallis AE, Economou JS, Chiang CS. Interleukin-3 in gene therapy of cancer. Folia Biol (Praha) 1994; 40: 62-73.
36. Bubenik J, Zeuthen J, Bubenikova D, Simova J, Jandlova T. Gene therapy of cancer: use of IL-2- gene transfer and kinetics of local T and NK cell subsets. Anticancer Res 1993; 13: 1457-60.
37. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-9.
38. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
39. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
40. Tsai SC, Gansbacher B, Tait L, Miller FR, Heppner GH. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst 1993; 85: 546-53.
41. Fakhrai H, Shawler DL, Gjerset R, Naviaux R, Royston I, Sobol RE. Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Human Gene Ther 1995; 6: 591-601.
42. Shawler DL, Dorigo O, Gjerset RA, Royston I, Sobol RE, Fakhrai H. Comparison of gene therapy with interleukin-2 (IL-2) gene modified fibroblasts and tumor cells in the murine CT-26 model of colorectal carcinoma. J Immunother 1995; 17 (Suppl. 4): 201-8.
43. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991; 11: 3125-31.
44. Platzer C, Richter G, Uberla K, Hock H, Diamantstein T, Blankenstein T. Interleukin-4 mediated tumor suppression in nude mice involves interferon-γ. Eur J Immunol 1992; 22: 1729-33.
45. Richter G, Kruger-Krasagakes S, Hein G, et al. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993; 53: 4134-7.
46. McBride WH, Dougherty GD, Walis AE, Economou JS, Chiang CS. Interleukin-3 in gene therapy of cancer. Folia Biologica (Praha) 1994, 40: 62-73.
47. Santin AD, Ioli GR, Hiserodt JC, et al. Development and characterization of an IL-4-secreting human ovarian carcinoma cell line. Gynecol Oncol 1995; 58: 230-9.
48. Gamboa G, Carpenter PM, Podnos YD, et al. Characterization and development of UCI107, a primary human ovarian carcinoma cell line. Gynecol Oncol 1995; 58: 336-43.
49. Santin AD, Ioli GR, Hiserodt JC, et al. Development and in vitro characterization of a GM-CSF secreting human ovarian carcinoma tumor vaccine. Int J Gynecol Cancer 1995, 5: 401-10.
50. Sulitzenau D. Immunosuppressive factors in human cancer. Adv Cancer Res 1993; 60: 247-67.
51. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor betal. Cancer Research 1992; 52: 1386-92.
52. Kuppner MC, Hamou M, Sawamura Y, Bodmer S, Tribolet N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta2. J Neursurg 1989; 71: 211-17.
53. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA. Transforming growth factor-beta inhibits the in vitro generation of lymphokine activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 1988; 26: 95-100.
54. Chegini N, Williams RS. Immunocytochemical localization of transforming growth factors (TGFs) TGF-alpha and TGF-beta in human ovarian tissues. J Clin Endocrinol Metabol 1992; 74: 973-80.
55. Bartlett JM, Rabiasz GJ, Scott WN, Langlon SP, Smyth JF, Miller WR. Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells. Br J Cancer 1992; 65 (Suppl. 5): 655-60.
56. Jozan S, Guerrin M, Mazars P, et al. Transforming growth factor β1 (TGF-β1) inibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. Internat J Cancer 1992; 52: 766-70.
57. Hirte W, Clarke DA, O'Connell G, Rusthoven J, Mazurka J. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol 1992, 142: 207-16.
58. Hirte H, Clark DA. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 1991; 32: 296-302.
59. Berek JS, Lichtenstein AK, Knox RM, et al. Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model. Cancer Res 1985; 45: 4215-18.
60. Itoh Y, Koshita Y, Takahashi M, Watanabe N, Kohgo Y, Niitsu Y. characterization of tumor-necrosis-factor-gene transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production. Cancer Immunol Immunother 1995; 40: 95-102.
61. Hwu P, Rosenberg SA. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. Cancer Detect Prev 1994; 18: 43-50.
62. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T -cell receptor genes. Cancer Res 1995; 55: 3369-73.
63. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 1993; 178: 361-6.
64. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994; 24: 605-10.
65. Thomas R, Davis LS, Lipsky PE. Isolation and characterisation of human peripheral blood dendritic cells. J Immunol 1993; 150: 821-34.
66. Young JW, Steinman RM. Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper cells. J Exp Med 1990; 171: 1315-32.
67. Young JW, Koulova L, Soergel SA, Clarke EA, Steinman RM. The B7/BB-1 antigen provides one of several co-stimulatory signals for the activation of CD4+T lymphocytes by human blood DC in-vitro. J Clin Invest 1992; 90: 229-39.
68. Steinman RM. The dendritic cell system and its role in immunogenicity. Rev Immunol 1991; 271-96.
69. Yamasaki S, Okino T, Chakraborty NG, et al. Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients. Cancer Immunol Immunother 1995; 40 (Suppl. 4): 268-71.
70. Kuiper M, Peakman M, Farzaneh F. Ovarian tumour antigens as potential targets for immune gene therapy. Gene Ther 1995; 2: 7-15.
71. Varmus H. Oncogenes and the Molecular Origins of Cancer. New York: Cold Spring Harbor Press, 1989: 3-44.
72. Hung MC, Matin A, Zhang Y, et al. HER-2/neu targeting gene therapy - a review. Gene 1995; 159: 65-71.
73. Van Dam PA, Vergote IB, Lowe DG, et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 1994; 47: 914-19.
74. Bauknecht T, Angel P, Kohler M, et al. Gene structure and expression analysis of the epidermal growth factor-alpha, myc, jun, and metallothionein in human ovarian carcinomas. Cancer 1993; 71 (Suppl. 2): 419-29.
75. Rubin SC, Finstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994; 73: 1456-9.
76. Fajac A, Benard J, Lhomme C, et al. c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariante analysis. Int J Cancer 1995; 64: 146-51.
77. Deshane J, Cabrera G, Grim JE, et al. Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single-chain antibody [see comments]. Gynecol Oncol 1995; 59: 8-14.
78. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-6.
79. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-9.
80. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 90: 4961-5.
81. Runnebaum IB, Tong XW, Moebus V, et al. Multiplex PCR screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum Genet 1994; 93: 620-4.
82. Berchuck A, Kohler MF, Marks JR, et al. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994; 170: 246-52.
83. Santoso JT, Tang DC, Lane SB, et al. Adenovirus-based p53 gene therapy in ovarian cancer [see comments]. Gynecol Oncol 1995; 59: 171-8.
84. Skilling JS, Squatrito RC, Connor JP, Niemann T, Buller RE. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol Oncol 1996; 60: 72-80.
85. Pisa P, Halapi E, Pisa EK, et al. Selective expression of interleukin 10, Interferon γ, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. Proc Natl Acad Sci USA 1992; 89: 7708-12.
86. Havrilesky LJ, Hurteau JA, Whitakers RS, et al. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor betal. Cancer Research 1995; 55: 944-8.
87. Hurteau J, Rodriguez GC, Whitaker RS, et al. Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 1995; 74: 93-9.
88. Tseng BY, Brown KD. Antisense oligonucleotide technology in the development of cancer therapeutics. Cancer Gene Ther 1994; 1: 65-71.
89. Wu S, Meeker WA, Wiener JR, et al. Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. Gynecol Oncol 1994; 53: 59-63.
90. Watson JM, Berek JS, Martinez-Maza O. Growth inhibition of ovarian cancer cells induced by antisense IL-6 oligo-nucleotides. Gynecol Oncol 1993; 49: 8.
91. Wills KN, Huang WM, Harris MP, et al. Gene therapy for hepatocellular carcinoma: Chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther 1995; 2: 191-7.
92. Kun LE, Gajjar A, Muhlbauer M, et al. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 1995; 6: 1231-55.
93. Ido A, Nakata K, Kato Y, et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995; 55: 3105-9.
94. Macri P, Gordon JW. Delayed morbidity and mortality of albumin/SV40 T-antigen transgenic mice after insertion of an alpha-fetoprotein/herpes virus thymidine kinase transgene and treatment with ganciclovir. Human Gene Ther 1994; 5: 175-82.
95. Freeman SM, Ramesh R, Shastri M, Munshi A, Jensen AK, Marrogi AJ. The role of cytokines in mediating the bystander effect using HSV-TK xenogenic cells. Cancer Letters 1995; 92: 167-74.
96. Elshami AA, Kucharczuk JC, Sterman DH, et al. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222: 298-307.
97. Holzmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas [see comments]. J Natl Cancer Inst 1992; 84: 1486-91.
98. Sorrentino BP, McDonagh KT, Woods D, Orlic D. Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 1995; 86: 491-501.
99. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99-103.
100. Deisseroth AB, Kavanagh J, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther 1994; 5: 1507-22.